Ground-breaking Lipid Nanoparticles, patented for efficient delivery of RNA-based vaccines and therapeutics, offer long-term stability at ambient temperatures, eliminating the need for costly cold-chain storage.
This innovation ensures high efficacy for at least 12 months, whether in aqueous or powder form, even in tropical climates reaching up to 40°C. With a validation study underway with a world-leading pharmaceutical company, our spinout aims to license-out and co-develop our technologies with RNA vaccines and therapeutics developers.
Media:
About us | Research groups | 51³Ô¹ÏÍø
GSK and 51³Ô¹ÏÍø to eliminate costly cold-chain storage of RNA vaccines | 51³Ô¹ÏÍø News | 51³Ô¹ÏÍø